Biotech Hub

Biohaven is eyeing filing for approval early next year for its experimental pain spray after new data showed it hit its primary endpoints in a phase 3 test.

The biotech industry is “getting there” in terms of advancing LGBTQ+ inclusion, but it’s an effort that remains in the early innings. Fierce Biotech spoke with more than 20 LGBTQ+ leaders in biopharma…

In the course of its combination with special purpose acquisition company Odyssey—which went public in a 300 million euro IPO of its own earlier this year—BenevolentAI will rake in up to 390 million…

Using stem cell models derived from Alzheimer’s patients, researchers at the Cleveland Clinic discovered that the erectile dysfunction drug Viagra (sildenafil) targets tau, one of the proteins…

Adicet Bio makes its therapies from gamma delta T cells, a rare type of immune cell that the company believes offer advantages compared to other cell therapies. The company now has early Phase 1 data…

RefleXion Medical is aiming to develop radiation therapy capable of destroying metastatic cancer—by using the cancer itself as a tour guide through the areas of the body where it has already spread.

The secret use of consumer data by Medicare Advantage plans raises important issues about disclosure and transparency.

The USPTO should be a pivotal federal agency for influencing drug pricing. A new director could point it in that direction.

Patients are clashing with their providers in conversations about the side effects they say they experience while on hormonal contraception.

Policies to manage or halt the spread of SARS-CoV-2 have led to increased violence against women and girls around the world.